BioLife Solutions, Inc.
- Open
- 30.09
- Day high
- 30.88
- Day low
- 28.50
- Prev close
- 30.26
- Volume
- 1.4M
- Mkt cap
- $1.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.8
- P/S
- 14.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$28.1M over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions mixed (13F)
BioLife Solutions, Inc. (BLFS) is a Healthcare company listed on NASDAQ. The stock is up 40% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
BioLife Solutions, Inc. (BLFS) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BLFS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.01 | $0.04 | +300.0% | $28M | +7.2% |
| Aug 7, 2025 | $-0.02 | $-0.33 | -1556.7% | $25M | -1.0% |
| May 8, 2025 | $-0.03 | $0.04 | +233.3% | $24M | +7.7% |
| Mar 3, 2025 | $-0.06 | $-0.01 | +83.3% | $3M | -84.3% |
| Aug 8, 2024 | $-0.14 | $-0.06 | +57.1% | $28M | +18.3% |
| May 9, 2024 | $-0.26 | $-0.19 | +26.9% | $32M | +22.0% |
| Feb 29, 2024 | $-0.36 | $-0.30 | +16.7% | $33M | -2.0% |
| Nov 9, 2023 | $-0.38 | $-0.67 | -76.3% | $33M | -1.5% |
| Mar 16, 2023 | $-0.19 | $-1.15 | -505.3% | $44M | +2.3% |
| Nov 9, 2022 | $-0.18 | $-0.23 | -27.8% | $41M | -3.1% |
| Aug 9, 2022 | $-0.20 | $-1.71 | -755.0% | $41M | +3.5% |
| Feb 28, 2022 | $-0.16 | $-0.37 | -131.3% | $37M | +4.2% |
BLFS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 13, 2026 | Berard Toddofficer: Chief Marketing Officer | Tax | 293 | $27.79 |
| Jul 13, 2026 | Wichterman Troyofficer: Chief Financial Officer | Tax | 844 | $27.79 |
| Jul 13, 2026 | Mathew Aby J.officer: EVP & Chief Scientific Officer | Tax | 516 | $27.79 |
| Jun 22, 2026 | Berard Toddofficer: Chief Marketing Officer | Tax | 470 | $26.04 |
| Jun 22, 2026 | Mathew Aby J.officer: EVP & Chief Scientific Officer | Tax | 564 | $26.04 |
| Jun 22, 2026 | Wichterman Troyofficer: Chief Financial Officer | Tax | 937 | $26.04 |
| Jun 22, 2026 | Werner Seanofficer: Chief Technology Officer | Tax | 420 | $26.04 |
| Jun 22, 2026 | DE GREEF RODERICKdirector, officer: President and CEO | Tax | 2,775 | $26.04 |
| Jun 10, 2026 | Wichterman Troyofficer: Chief Financial Officer | Tax | 1,026 | $26.10 |
| Jun 10, 2026 | Mathew Aby J.officer: EVP & Chief Scientific Officer | Tax | 627 | $26.10 |
| Jun 10, 2026 | Berard Toddofficer: Chief Marketing Officer | Tax | 356 | $26.10 |
| May 21, 2026 | Casdin Partners Master Fund, L.P.10 percent owner | Sell | 650,000 | $23.70 |
| May 21, 2026 | Casdin Partners Master Fund, L.P.10 percent owner | Sell | 300,000 | $22.65 |
| May 21, 2026 | Casdin Partners Master Fund, L.P.10 percent owner | Sell | 250,000 | $23.70 |
| Apr 10, 2026 | Wichterman Troyofficer: Chief Financial Officer | Tax | 844 | $19.27 |
Source: BLFS SEC Form 4 filings, latest Jul 13, 2026. For informational purposes only — not investment advice.
See the full BLFS insider & 13F page →BioLife Solutions, Inc. company profile
Overview
BioLife Solutions, Inc. (NASDAQ:BLFS) is a specialized biotechnology company founded in 1987 and headquartered in Bothell, Washington. The company went public in 1989 and has evolved into a leading provider of bioproduction tools and services specifically designed for the cell and gene therapy industry. Over its decades-long history, BioLife has strategically focused on developing and manufacturing critical preservation and processing solutions that enable the safe storage, transport, and manufacturing of biological therapies. The company has recently undergone significant portfolio reshaping, divesting non-core businesses to concentrate on its higher-margin cell processing platform, positioning itself as a key enabler in the rapidly growing cell and gene therapy market.
Business
BioLife Solutions operates in the specialized biotechnology tools and services sector, specifically serving the cell and gene therapy (CGT) industry. Cell and gene therapies represent a revolutionary approach to medicine where living cells or genetic material are used to treat diseases, often involving the modification of a patient's own cells to fight cancer or genetic disorders. The company's business is organized around three main segments, though it has been strategically divesting non-core operations: Cell Processing Platform (approximately 90% of current revenue focus): This is the company's core business, centered around biopreservation media products. These are specialized chemical formulations that protect cells during freezing, storage, and thawing processes. The flagship products include HypoThermosol FRS and CryoStor, which are designed to prevent cell damage and death that typically occurs during preservation. The platform also includes CellSeal vials, human platelet lysate (hPL) for cell culture, and ThawSTAR automated thawing equipment. These products are critical because cell and gene therapies involve living materials that are extremely sensitive to temperature changes and preservation conditions. Evo Cold Chain Platform (small revenue contribution): This segment provides cloud-connected passive storage and transport containers specifically designed for temperature-sensitive biologics and pharmaceuticals. These containers ensure that cell and gene therapy products maintain proper temperatures during shipping from manufacturing facilities to treatment centers. Divested/Divesting Segments: The company has sold or is exiting its biostorage services business (SciSafe) and freezer manufacturing operations (Custom Biogenic Systems and Stirling ULT) to focus resources on the higher-margin cell processing platform. BioLife's products are essential infrastructure for the CGT industry because these therapies require precise preservation conditions to maintain cell viability and therapeutic efficacy from manufacturing through patient administration.
Revenue model
BioLife Solutions generates revenue primarily through product sales of consumable biopreservation media and related cell processing tools. The company's business model is built around recurring revenue from consumable products that are used each time a cell or gene therapy is manufactured, processed, or administered. The primary revenue streams include: Biopreservation media sales which represent the majority of revenue, sold as consumable solutions used in each therapy manufacturing batch. Cell processing tools including specialized vials, culture supplements, and automated equipment sold to therapy manufacturers. Cold chain transport solutions through the evo platform, generating revenue from container sales and associated services. BioLife's customers are primarily biopharmaceutical companies developing and manufacturing cell and gene therapies, contract development and manufacturing organizations (CDMOs) that provide manufacturing services to therapy developers, and academic research institutions conducting CGT research. The company's top 20 customers account for approximately 80% of biopreservation media revenue, with about 40% of revenue coming from customers with already-approved commercial therapies. Several factors influence BioLife's margins and profitability. Positive margin drivers include the company's estimated 70% market share in CGT clinical trials, creating pricing power; the consumable nature of products generating recurring revenue; the critical nature of products making customers less price-sensitive; and the ability to cross-sell multiple products to increase revenue per therapy dose by 2-3x. Margin pressures could come from increased competition as the market grows; customer consolidation potentially reducing pricing power; regulatory changes affecting the CGT industry; and the need for continued R&D investment to maintain technological leadership. The company has been implementing selective price increases and optimizing customer contracts to improve margins while focusing on premium product positioning rather than competing on price.
Competitive moat
BioLife Solutions possesses a moderate but defensible moat built primarily on scientific expertise, regulatory positioning, and switching costs. The company's strongest competitive advantage lies in its deep technical knowledge of cell preservation chemistry and its established position as the de facto standard in biopreservation media, with products embedded in approximately 70% of commercially-sponsored CGT clinical trials and 17 approved therapies. The moat is strengthened by several factors: High switching costs exist because changing preservation media requires extensive regulatory validation and clinical testing, making customers reluctant to switch once a therapy is in development. Regulatory barriers create protection since biopreservation media becomes part of the approved manufacturing process for therapies, requiring regulatory approval to change. Technical expertise accumulated over decades provides advantages in formulation chemistry and understanding of cell preservation mechanisms. Customer relationships built through the long development cycles of CGT therapies create stickiness. However, the moat faces potential challenges. The company primarily competes against "home-brew" formulations that customers develop internally, rather than sophisticated commercial competitors. As the CGT market grows and becomes more lucrative, larger pharmaceutical companies or specialized biotechnology firms could invest in developing competing preservation solutions. The relatively small scale of the current market means that major players haven't yet focused significant resources on this space, but this could change as the market expands. Additionally, technological disruption could emerge from novel preservation approaches or manufacturing process innovations that reduce dependence on traditional cryopreservation. The company's recent acquisition of PanTHERA CryoSolutions represents an attempt to stay ahead of potential technological shifts by developing next-generation preservation technologies that could operate at higher temperatures and with lower toxicity. Overall, BioLife's moat is meaningful but not impregnable, requiring continued innovation and relationship management to maintain its market position as the industry matures.
Risks & safety
BioLife Solutions demonstrates a strong financial safety profile with minimal solvency risk and a solid balance sheet position. Liquidity and Debt Position: • Cash and short-term investments: $66.9 million (Q1 2025) • Total debt minimal with debt-to-equity ratio of 0.076 • Current ratio of 4.73 indicating strong short-term liquidity • Free cash flow positive at $1.6 million in Q1 2025 • No significant debt maturities or cash burn concerns Valuation Metrics: • Trading at 3.05x book value • EV/EBITDA of 1,561x due to minimal EBITDA ($166k in Q1) • Revenue multiple appears reasonable given 30% growth rates • Graham net-net ratio of 1.42 suggests adequate asset backing Other Considerations: • Strong balance sheet with $352.6 million in shareholders' equity • Recent strategic divestitures improved cash position • Recurring revenue model from consumable products provides stability • Market leadership position in growing CGT industry reduces business risk • Conservative capital structure with minimal leverage
Recent development
Over the past few years, BioLife Solutions has undergone significant strategic transformation focused on streamlining operations and concentrating on its core cell processing platform. The most notable development was the divestiture of non-core businesses, including the sale of the SciSafe biostorage business for $73 million in cash and the decision to exit the Custom Biogenic Systems (CBS) freezer business. These moves strengthened the balance sheet and allowed management to focus resources on higher-margin, recurring revenue opportunities. The company has made strategic acquisitions to enhance its technology portfolio, most recently acquiring PanTHERA CryoSolutions to develop next-generation cryopreservation products. This acquisition aims to create preservation solutions with improved efficacy, lower DMSO concentrations, and the ability to preserve cells at -80°C instead of the traditional -196°C, potentially reducing storage and shipping costs for customers. Commercial expansion efforts have focused on increasing market penetration and cross-selling opportunities. The company has consolidated sales and marketing under a new Chief Commercial Officer and implemented pricing optimization strategies with key customers. Management has been working to increase revenue per patient dose by 2-3x through integration of multiple products from their cell processing portfolio into customer manufacturing processes. Product development initiatives have centered on expanding the consumable product lines and improving existing offerings. The company has been developing accessories for automated fill devices, enhancing the CryoCase product line, and working on next-generation biopreservation formulations. The focus remains on consumable products that generate recurring revenue rather than capital equipment sales. The strategic pivot has resulted in a more focused business model with improved margins, as evidenced by adjusted EBITDA margins expanding from 6% to 24% year-over-year, while maintaining strong growth in the core cell processing platform with 30%+ revenue increases.
BLFS company profile · for informational purposes only — not investment advice.
Track BLFS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free